Dr. Heidi Ko is board certified in Internal Medicine, Hematology and Medical Oncology. She received her medical degree from Rowan University School of Osteopathic Medicine in Stratford, NJ and her Internal Medicine training at McGovern Medical School at UT Health in Houston, TX. Dr. Ko completed her Hematology and Oncology fellowship training at Montefiore Medical Center/Albert Einstein College of Medicine in Bronx, NY. After her fellowship, Dr. Ko worked as a hematologist and medical oncologist in Houston and, most recently, worked as a breast medical oncologist at UT Health San Antonio-Mays Cancer Center in San Antonio, TX.
- Jun 07, 2025 Utilization of a Multi-modal Comprehensive Genomic and Immune Profiling Testing Strategy Results in a High Rate of Test Success and Detection of Clinically Relevant Biomarkers While Optimizing Tissue Usage
- May 31, 2025 Unveiling the differences in tumor immune microenvironment between KRAS-wildtype and KRAS-mutant pancreatic ductal adenocarcinoma
- Nov 23, 2024 Comprehensive genomic and immune profiling for the detection of clinically significant tumor biomarkers
- Oct 30, 2024 Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer - a case series of divergent results from a large reference laboratory
- Oct 29, 2024 A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors
- Apr 29, 2024 Immunologic factors associated with differential response to neoadjuvant chemoimmunotherapy in triple negative breast cancer
- Apr 07, 2024 Landscape of HIF-1-alpha expression across 24,186 solid tumors using comprehensive immune profiling
- Apr 07, 2024 Landscape of TIGIT and PD-L1 co-expression in solid tumors
- Mar 19, 2024 The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
- Feb 12, 2024 Comprehensive Genomic Testing: Tissue Stewardship and Best Practices
- Dec 11, 2023 Findings of clinically significant variants (Tier IA) with comprehensive genomic profiling in a breast cancer patient cohort
- Dec 11, 2023 Comprehensive immune profiling reveals factors associated with neoadjuvant chemotherapy response in triple negative breast cancer
- Nov 17, 2023 Non-V600 BRAF mutated melanomas have immune microenvironments primed for immune checkpoint inhibitor response
- Nov 17, 2023 Genomic stability of prostate cancers with homologous recombination gene alterations
- Nov 17, 2023 Genomic landscape of ERBB2 alterations in solid tumors without an approved HER2-targeted therapy
- Nov 17, 2023 Validation of a tumor-informed HLA typing assay to support drug development and clinical decision making
- Nov 14, 2023 Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
- Nov 03, 2023 Molecular and immune profiling of lobular-enriched versus non-lobular invasive breast cancers
- Nov 03, 2023 Comprehensive genomic and immune profiling of ALK fusion-positive and negative lung adenocarcinomas
- Nov 03, 2023 Comprehensive genomic and immune profiling (CGIP) reveals a distinct genomic and immune gene expression profile for younger patients with non-small cell lung cancer (NSCLC)
- Nov 03, 2023 Immune microenvironment of primary versus metastatic melanoma of the brain
- Nov 03, 2023 Metastatic triple negative breast cancer has distinct tumor immune landscape
- Nov 01, 2023 Comprehensive Genomic and Immune Profiling of Early-Onset Colorectal Cancer
- Jun 04, 2023 Comparison of immune microenvironment between primary and metastatic breast tumors
- Jun 01, 2023 Evolving landscape of HER2-low breast cancer: New diagnosis and treatment paradigm shift
- Feb 14, 2024 Cancer testis antigen burden (CTAB): a novel biomarker of tumor‑associated antigens in lung cancer